Schizoaffective Disorder

Long-acting injectable antipsychotic medications reduced hospital readmission rates among patients with schizophrenia and schizoaffective disorder compared with oral antipsychotic medications, according to a recent study.

An investigational, weekly oral dose of risperidone for schizophrenia achieved drug levels comparable to daily Risperdal in a phase 3 study involving Lynx, a long-acting drug delivery platform developed by Lyndra Therapeutics.

Atopic dermatitis was associated with increased odds for schizophrenia and schizoaffective disorder, according to a study published in Archives of Dermatological Research.

A biopharmaceutical company announced it has dosed the first patient in a clinical trial of a long-acting oral treatment for schizophrenia, schizoaffective disorder and bipolar I disorder, according to a company press release.

Individuals with serious mental illnesses such as bipolar disorder and schizophrenia may experience greater 10- and 30-year CV risk compared with those without a serious mental illness, researchers reported.

Antipsychotic treatment did not increase risk for mortality among adults with serious mental illness diagnosed with COVID-19 infection, according to study results in a research letter published in JAMA Psychiatry.

An oral, ultra-long-acting, extended-release risperidone capsule provided sustained therapeutic levels of risperidone over 1-week dosing intervals, according to results of a randomized, parallel group, placebo-controlled study.

Researchers have found evidence countering the hypothesis that a long duration of untreated psychosis is associated with “insidious, severe psychotic disorder,” as well as against the toxicity of untreated psychosis, according to study findings published in American Journal of Psychiatry.

Researchers have identified psychosis subgroups that may inform ongoing efforts to redefine psychosis taxonomy using updated criteria, according to results of a longitudinal cohort study published in JAMA Psychiatry.

An interactive voice response system that uses artificial intelligence effectively monitored the well-being of patients with serious mental illness, according to study findings published in PLOS One.